SL 325
Alternative Names: SL-325Latest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Shattuck Labs
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Tumour necrosis factor member 25 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 01 Oct 2024 Shattuck Labs plans to file an IND application for Inflammatory bowel disease in the third quarter of 2025
- 01 Oct 2024 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral)
- 01 Oct 2024 Pharmacodynamics data from preclinical studies in Inflammatory bowed disease released by Shattuck Labs